[
    [
        {
            "time": "",
            "original_text": "医药行业周报：第三轮全国集采脚步临近 持续关注原料药制剂一体化公司",
            "features": {
                "keywords": [
                    "医药行业",
                    "全国集采",
                    "原料药",
                    "制剂一体化"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业周报：第三轮全国集采脚步临近 持续关注原料药制剂一体化公司",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：国内第一个重组新冠疫苗已进入临床试验阶段 完成首针接种",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重组新冠疫苗",
                    "临床试验",
                    "首针接种"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：国内第一个重组新冠疫苗已进入临床试验阶段 完成首针接种",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报(第二十六周)",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业周报"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业周报(第二十六周)",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "智飞生物(300122)公司点评：重组亚单位新冠疫苗获批临床 研发管线持续丰富",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重组亚单位新冠疫苗",
                    "临床",
                    "研发管线"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物(300122)公司点评：重组亚单位新冠疫苗获批临床 研发管线持续丰富",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]